2023-01-20 12:49Company Overview - BeiGene has over 9,000 colleagues across approximately 40 offices on 5 continents[7] - The company has over 950 oncology research team members[8] - BeiGene has a global commercial team of over 3,500 people[7] - The company has 16 approved products[7] - BeiGene's annual product revenue is over $1 billion, with a 109% product revenue growth[7] - The company's cash balance is over $5 billion[7] Clinical Development and Portfolio - BeiGene has approximately 50 assets in clinical and commercial stages[8] - The company has over 60 pre-clinical programs, with the majority having first-in-class potential[8] - BeiGene has conducted over 15 global phase 3 registration trials[14] - The company has initiated over 110 clinical trials with over 20,000 subjects enrolled[14] - BeiGene expects 10+ INDs (Investigational New Drug applications) per year starting in 2024[11] BRUKINSA (Zanubrutinib) - BRUKINSA demonstrated superior efficacy versus ibrutinib in R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia) in the ALPINE trial, with improved ORR (Overall Response Rate) and PFS (Progression-Free Survival)[17] - In the ALPINE trial, BRUKINSA showed a PFS of 79.5% compared to 67.3% for Ibrutinib[19] - BRUKINSA also demonstrated a favorable safety profile versus ibrutinib, with an improved cardiac profile[17] - Serious cardiac adverse events were reported in 1.9% of patients on BRUKINSA compared to 7.7% on Ibrutinib[46] - BRUKINSA is now approved in over 60 markets[57] Tislelizumab - The global market for PD-1/PD-L1 class drugs is estimated to reach $55 billion by 2026[64] - BeiGene is eligible for $1.5 billion collaboration revenue from Novartis for Tislelizumab in North America, Europe, and Japan[64] Financial Strength - BeiGene had a $5.1 billion cash position as of Q3 2022[65] - The company is eligible for up to $3.6 billion in collaboration revenue[65]